DAVITA INC.
DVA US23918K1088
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,000 facilities worldwide, mostly in the us, and treats about 250,000 patients globally each year. Government payers dominate us dialysis reimbursement. DaVita receives about two thirds of us sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of the us patients treated, they represent nearly all of the profits generated by DaVita in the us dialysis business.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -2% | -35% | 40% | 40% | 2% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Hearty James O SR OFF |
150.00 USD |
2,351 Sold |
352,650 USD |
23/07/2025 | 23/07/2025 |
| Waters Kathleen Alyce SR OFF |
167.96 USD |
5,239 Sold |
879,942 USD |
27/11/2024 | 27/11/2024 |
| Rodriguez Javier CEO |
165.05 USD |
50,000 Sold |
8,252,515 USD |
13/09/2024 | 16/09/2024 |
| Ackerman Joel CFO |
163.56 USD |
36,684 Sold |
6,000,035 USD |
16/09/2024 | 16/09/2024 |
| Rodriguez Javier CEO |
162.85 USD |
9,881 Sold |
1,609,122 USD |
13/09/2024 | 13/09/2024 |
| Waters Kathleen Alyce SR OFF |
154.85 USD |
12,916 Sold |
2,000,043 USD |
28/08/2024 | 28/08/2024 |
| Ackerman Joel CFO |
155.02 USD |
4,740 Sold |
734,785 USD |
27/08/2024 | 28/08/2024 |
| Rodriguez Javier CEO |
155.93 USD |
7,943 Sold |
1,238,589 USD |
26/08/2024 | 27/08/2024 |
| Ackerman Joel CFO |
155.06 USD |
64,029 Sold |
9,928,586 USD |
27/08/2024 | 27/08/2024 |
| Rodriguez Javier CEO |
155.93 USD |
32,176 Sold |
5,017,303 USD |
26/08/2024 | 26/08/2024 |